Preoperative Condition in Giant Obese Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

January 31, 2018

Study Completion Date

April 30, 2018

Conditions
Morbid ObesityBariatric Surgery Candidate
Interventions
DRUG

Liraglutide

Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)

OTHER

Aminosteril hepa 8%

Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)

DIETARY_SUPPLEMENT

Caloric diet with 1000 kcal

Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 1000 kcal from day 1 onwards till technical operability is achieved (about 21 days)

Trial Locations (1)

63069

Sana Klinikum Offenbach, Offenbach

All Listed Sponsors
lead

Sana Klinikum Offenbach

OTHER

NCT02616003 - Preoperative Condition in Giant Obese Patients | Biotech Hunter | Biotech Hunter